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Abstract. Human chronic myelogenous leukemia (CML) is a
malignancy of pluripotent hematopoietic cells characterized by
a distinctive cytogenetic abnormality resulting in the creation
of a p210 Bcr-Abl fusion protein with abnormal tyrosine kinase
activity. Recently, a selective Abl kinase inhibitor, Imatinib
mesylate, was introduced as a first line therapy for CML.
Despite the initial response, CML patients develop a
resistantance to Imatinib, which is mediated mainly by point
mutations within the Abl protein. Herein, we describe the
identification of mycelium organic extracts of Daedalea
gibbosa with selective anti-proliferating and apoptosis-
inducing activities against K562 cells and other laboratory
model of CML. Using activity-guided purification, we
isolated an active fraction, F6, which inhibits in vitro kinase
activity of recombinant Abl. The active fraction significantly
inhibits the autophosphorylation of native and mutated Bcr-
Abl, which are resistant to Imatinib treatment including the
T315I mutation. Using a colony-forming assay, we demon-
strated that the active fraction is effective in inhibiting the
colony formation of the Ba/F3 cell line harboring either native
Bcr-Abl or its mutations, including the T315I mutation. Our
data illustrated the potential of natural products in cancer
therapeutics.
Introduction
Medicinal mushrooms have been an important source of
therapeutic substances for the treatment of various human
illnesses (1). Higher basidiomycetes mushrooms (HBM)
represent a major and, as yet, largely untapped source of
potent new pharmaceutical products. Of the 15,000 known
species, 2,000 are safe for human health and ~650 of them
possess medicinal properties (2). Of the 650 mushroom species
with known medicinal properties, only ~20 species are already
in use (3), arguing the need to explore the medicinal potential
of the rest.
Several medicinal mushroom substances having anti-tumor
activity were isolated including lentinan, krestin and schizo-
phyllan. Most bioactive substances isolated from mushrooms
were high-molecular-weight (HMW) polysaccharides having
a molecular weight of 200-400,000 Dalton. Anti-tumor
activity of HMW polysaccharides was attributed to immune-
modulation function or enhancement properties of the immune
system, not as a result of a direct influence on the tumor cells.
Our interest is in low-molecular-weight (LMW) moieties that
can easily penetrate the cell membrane and exhibit anti-tumor
activity with a defined mechanism of action (4-8).
Chronic myelogenous leukemia (CML) is a clonal
myeloproliferative disorder of hematopoietic stem cells
and accounts for 15% of leukemias in adults (9). Blasts of
patients suffering from CML in >95% of cases the Philadelphia
chromosome, the morphological substrate of t(9;22). Patients
(25-30%) from adult lymphoblastic leukemia (ALL) are Ph+
ALL and the presence of t(9;22) defines a high-risk subgroup
of ALLs (9).
The t(9;22)-related translocation products are the Bcr-Abl
fusion proteins. The fusion of Bcr to Abl leads to the
constitutive activation of the kinase activity of Abl, whose
physiological counterpart is finely regulated by a variety of
stimuli. Constitutively activated Abl induces aberrant
proliferation and neoplastic transformation by the constitutive
activation of RAS, PI3 kinase, as well as JAK/STAT (9). The
constitutively activated Abl kinase activity is indispensable for
the Bcr-Abl-induced transformation of cells. The Bcr-Abl-
induced phenotype of hematopoietic cells is characterized by
increased proliferation as well as by reduced susceptibility to
a variety of pro-apoptotic stimuli, including growth factor
deprivation (9). The inoculation of stem cells retrovirally
transduced with Bcr-Abl induces a CML-like disease in sub-
lethally irradiated recipient mice within 3-4 weeks, which
proves that Bcr-Abl is responsible for the pathogenesis of Ph+
leukemias (10).
The inhibition of Bcr-Abl kinase activity is a valid concept
of causal therapy of Ph+ leukemia and the specific Abl kinase
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inhibitor Imatinib mesylate (Imatinib, Gleevec, and before
STI571) is now a part of standard therapy of chronic phase
CML (CP) and is included in most clinical trials for the
treatment of Ph+ ALL (11-13). Unfortunately, the clinical
efficacy of the treatment with Imatinib continuously decreases
with the advancement of the disease. Blast crisis, CML or
relapsed Ph+ ALL benefit from the treatment of Imatinib only
temporarily or not at all (14). Patients relapsing upon treatment
with Imatinib are resistant to further treatment with the drug.
Secondary resistance is mostly due to the acquisition of
point mutations in Bcr-Abl, which change the affinity of the
protein for Imatinib. More than 25 different substitutions of
amino acid residues of Bcr-Abl have been detected in CML
and Ph+ ALL patients (15-17). Such mutations can pre-exist
at the onset of treatment in a small subset of cells, which are
selected by the treatment with Imatinib (18). Even mutations
outside the kinase domain contribute to Imatinib resistance
by stabilizing the active conformation, which is not accessible
by Imatinib.
Several new Abl inhibitors were reported; AMN107, BMS-
354825 and VX-680. AMN107 is a novel ATP-competitive
inhibitor of Abl with increased potency compared with
Imatinib in inhibiting cellular proliferation and was also more
effective than Imatinib in inhibiting phosphorylation of p185
Bcr-Abl tyrosine kinase in cell lines and in primary ALL cells.
AMN107 is effective against a variety of cell lines expressing
Imatinib-resistant Bcr-Abl mutants, except for the T315I
mutation (29).
BMS-354825 is another novel compound, which is a dual
Src/Abl kinase inhibitor having a greater potency than Imatinib
and is active against 14 of the 15 Imatinib-resistant Bcr-Abl
mutants (16). The T315I mutation in the kinase domain of Abl
was resistant to inhibition by Imatinib, AMN107 and BMS-
354825 (19). VX-680 compound was developed as Aurora A
kinase inhibitor and later turned out to inhibit Abl kinase and
its mutants including T315I mutation by a novel mechanism
(20). Treatment of Imatinib-resistant patients carrying the
T315I with VX-680 resulted in a promising outcome (20,21).
Herein, we report the identification of a mycelium organic
extract from Daedalea gibbosa having selective anti-
proliferating and apoptosis-inducing activities against K562
cells and other laboratory model of CML. In addition, we
identified an active fraction, F6, capable of directly inhibiting
the kinase activity of recombinant Abl, as well as its autophos-
phorylation activity of native Bcr-Abl and its mutated forms
including the T315I mutation. The active fraction of D. gibbosa
also inhibited the colonigenicity of native Bcr-Abl and its
mutants when expressed in Ba/F3 cell lines.
Materials and methods
Mushroom material. The strain D. gibbosa used in the
present study is from the culture collection of HBM (HAI) of
the Institute of Evolution, University of Haifa, Israel (22).
Mushroom growth medium and the cultivation of D. gibbosa
as previously described (4).
Mushroom growth conditions and extractions. Pre-inocula for
cultures were prepared by transferring to 5-mm diameter
discs to flasks containing 100 ml of YE medium (yeast extract
0.1%, peptone 0.1%, glucose 2%, KH2PO4 0.1%, MgSO4
0.05%, supplemented with 10 ml/l of trace solution (18 mM
FeSO4, 3.7 mM MnSO4, 1.5 mM ZnSO4 and 0.8 mM CuSO4)
incubated for 14 days. The contents of the pre-inocula flasks
were homogenized and transferred to flasks containing 1 litre
of YE medium. Inoculated flasks were shaken at 160 r/min
at 27˚C for 12 days, then filtered and washed to remove
culture broth. Wet mycelia were dried at 37˚C. In the first phase
of the study; dry mycelium were extracted as previously
described (4). At a later stage, extraction was carried out
using 100% dichloromethane (DCM) or 100% ethyl acetate
(EA).
Fractionation of mycelium crude extract. Daedalea gibbosa
crude extract (1.5 g) was prepared from 85 g of D. gibbosa
mycelium, which was extracted with 5 litres of dichloro-
methane on a rotary shaker at 160 r/min at room temperature.
Dichloromethane extract (1.3 g) was separated in a silica gel
column (Silica gel 60, Merck, USA). Different fractions were
eluted by increasing methanol concentrations (from 0, 0.25,
0.5, 1, 2, 5, 10, 20, 40, 60 and 100%). During the fractionation
process, the eluted substances were traced by thin layer
chromatography (TLC). The separated substances were
visualized by staining with 2% phosphomolybdic acid.
Cell lines and cell cultures. Ba/F3 cells (a murine pro-B cell
line) transfected with native Bcr-Abl, Bcr-Abl/T315I, or
Bcr-Abl/E255K constructs were donated by Dr J. Duyster,
Germany. Transfected Ba/F3 and Human K562 (ATCC,
Rockville, MD) cell lines were grown in RPMI-1640 with
2 mM L-glutamine and supplemented with 10% fetal bovine
serum. Penicillin at 100 U/ml and streptomycin at 100 μg/ml
were added to the culture media. Each cell line was grown at
37˚C in a humidified atmosphere with 5% CO2.
Bcr-Abl autophosphorylation assay by ELISA. The capture
anti-Abl antibody (100 ng/well, Santa Cruz, USA) was first
diluted in 0.1 M carbonate buffer, pH 9.4, then 200 μl was
added to each well of a 96-well plate and the plates were kept
at 37˚C overnight. Cell lysates were prepared from treated
and untreated K562 or transfected Ba/F3 cell lines. After
treatment for 1 h, cells were washed twice with cold PBS and
lysed with lysis buffer [10 mM Tris-HCl (pH 7.4), 100 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM
Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol,
0.1% SDS, 0.5% deoxycholate, 1 mM phenylmethylsulfonyl
fluoride] for 30 min on ice. After blocking the plates for 1 h,
the cell lysates (100 μg/well) were diluted in a blocking buffer
(PBS, 1% BSA) and then added to the plates in a volume of
200 μl per well, and the plates were incubated at 4˚C
overnight. Subsequently, the plates were washed with wash
buffer (PBS, 0.05% Tween-20) and a reporter antibody PY20
conjugated to HRP was added at 50 ng/well and incubated at
room temperature for 1 h. The ELISA was developed using
TMB as a substrate and OD was measured at 630 nm.
Cellular autophosphorylation of Bcr-Abl. Ba/F3 cell lines
that express the native Bcr-Abl protein and its mutated forms
(4x105 cells/ml) were treated with mycelium crude extract,
fraction 6 of the D. gibbosa extract and DMSO for 1 h. Cells
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were collected, washed once with cold PBS and lysed as
previously indicated. Cell lysate supernatants (40 μg protein)
were resolved on 8% SDS-polyacrylamide gel electrophoresis,
transferred to nitrocellulose membranes and analyzed by
immunoblotting with phospho-c-Abl (Tyr245) polyclonal
antibody (Cell Signaling Technology, USA). Phosphorylated
levels of Bcr-Abl proteins were compared to total Abl, which
was detected using c-Abl monoclonal antibody (Santa Cruz
Biotechnology, USA).
Colony forming assay. Ba/F3 cells (2x103) that express Bcr-
Abl or its mutated forms (Bcr-Abl/T315I and Bcr-Abl/
E255K) were re-suspended in RPMI-1640 with L-glutamine,
supplemented with 10% fetal bovine serum and containing
0.3% Noble agar (Sigma, USA). Cells were seeded in 6-well
plates above a layer of 0.6% Noble agar. The cells were fed
every two days by overlaying the agar with 3 ml of a medium
containing mycelium crude extract, fraction 6 of D. gibbosa
extract, Imatinib or DMSO. The presence or absence of
colonies was scored after 14 days (23).
Abl in vitro kinase assay. The activity of Abl protein kinase
using recombinant Abl enzyme (expressed in Sf21 cells from
Upstate Cell Signaling Solutions, USA) was assayed in the
presence or absence of inhibitors by measuring the
incorporation of 33P from [γ-33P]-ATP (PerkinElmir, USA) into
Abltide (EAIYAAPFAKKK peptide from Upstate). Imatinib
(Novartis, Basel), AG957 (Sigma) and fraction 6 of D. gibbosa
(#514) mycelium crude extract were dissolved and stored at
-70˚C. The Abl protein kinase assay was carried out at 30˚C
in a total volume of 25 μl: 20 ng recombinant Abl kinase,
50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2,
0.2 mM Na3VO4, 1% DMSO, 25 μM ATP (1 μCi/assay [γ-33P]-
ATP) and 200 μg/ml Abltide and was carried out for 10 min.
The assay was terminated with the addition of 5 μl of 72 mM
EDTA. Subsequently, 25 μl of the reaction mixture were
transferred onto the center of a 2x2 cm P81 paper (Upstate
Cell Signaling Solutions), washed three times for 5 min with
0.75% phosphoric acid, then washed once for 5 min with
acetone and counted using a liquid scintillation analyzer
(TRI-CARB 2100TR, Packard Bio Science Company, USA).
Results
The medicinal mushroom D. gibbosa was grown as a
submerged culture, and four different solvent mixtures
including Eth (70% ethanol), E (33% ethyl acetate, 50%
methanol), H (22% ethyl acetate, 11% methanol) and C (33%
chloroform, 50% methanol) were used to prepare crude
extracts. Initially, growth inhibition activity of the various
extracts was monitored utilizing an XTT assay (4,24). The
anti-proliferation activity was evaluated using a number of
cell lines including HT29 (human colon adenocarcinoma
cells), MH3924A (rat Morris hepatoma) and DU145 (human
prostate carcinoma).
Results summarized in Table I show that each organic
extract of D. gibbosa was significantly active in inhibiting
the growth of K562 cells with varying potency and selectivity.
Crude extracts H (MH56) and C (MC57) were selective in
inhibiting the growth of K562 cells. In contrast, organic crude
extract Eth (Meth451) and E (ME424) show significant growth
inhibition activity against K562 and MH3924A (rat Morris
hepatoma) cell lines, though exhibit minimal activity against
HT29 (human colon adenocarcinoma cells) and DU145
(human prostate carcinoma).
Induction of erythroid differentiation in K562 by crude
extracts of Daedalea gibbosa. Overexpression of p210 Bcr-Abl is
implicated in mediating arrested differentiation and resistance
to apoptosis (25). K562 are patient-derived cell lines (26) and
serve as the in vitro CML model. K562 cell lines are
pluripotent cells that are able to undergo differentiation along
megakaryocytic and erythroid lineages (4,27). Induction of
differentiation in CML patients might serve as a potential route
for CML therapy. Extracts of D. gibbosa were evaluated for
their ability in inducing erythroid differentiation in K562 cell
lines. The ability to induce erythroid differentiation was
monitored by measuring hemoglobin production in treated
cells. Results shown in Table I demonstrate that crude extracts
of D. gibbosa show a varying potency in inducing hemoglobin
expression in treated cells. Extracts Meth451 and ME424
induce hemoglobin expression by 10.8- and 2.3-fold, respec-
tively, above the solvent-treated cells. Notably, extract Eth
shows the highest activity of hemoglobin production and was
more potent than that of butyric acid (4), a well established
differentiation agent.
Growth inhibition of K562 by D. gibbosa extracts is mediated
by the induction of the apoptosis pathway. Induction of
apoptosis is the principle mechanism by which the majority
of chemotherapeutic agents exert their function. The
execution of apoptosis requires specific caspases including
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Table I. Growth inhibition and induction of erythroid differentiation by D. gibbosa crude extracts.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Extracts Growth inhibition (%) Erythroid differentiation
––––––––––––––––––––––––– ––––––––––––––––––––––––––––––––––––––––– –––––––––––––––––––––––––
Ex Extract symbol K562 DU145 MH3924A HT-29 Relative hemoglobin levels
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Meth451 Eth 51.3 -6.2 44 0.2 10.8
MH56 H 56.3 26.2 28 23.9 1.6
ME424 E 45.4 11.9 54 24.50 2.3
MC57 C 52.7 16.2 14 7.6 1.7
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Percentage of growth inhibition caused to a variety of cell lines. Relative hemoglobin levels expressed in treated cells.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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caspase-3, which cleaves death substrates such as the nuclear
protein poly (ADP-ribose) polymerase (PARP). In this study,
we followed PARP cleavage as an endpoint for apoptosis
assessment (28).
Consistent with published data, treatment with AG957, a
known substrate inhibitor of Abl, causes a significant cleavage
of PARP. Crude extract E and Eth were active in inducing
apoptosis in treated K562 cell lines as determined by the
PARP cleavage assay (Fig. 1).
Effect of Daedalea gibbosa crude extract on the auto-
phosphorylation of Bcr-Abl. The creation of Bcr-Abl fusion
protein resulted in enhanced and uncontrolled tyrosine kinase
activity of the p210 Bcr-Abl. It is well documented that tyrosine
kinase activity is responsible for the oncogenic potential of
Bcr-Abl. A number of anti-CML compounds, including
Imatinib (Gleevec) and the tyrphostin AG957, are known to
inhibit tyrosine phosphorylation of Bcr-Abl and consequently
exert anti-CML effects. In order to investigate the mecha-
nism of action by which the organic extract of D. gibbosa
exerted its function, we followed levels of phosphorylated
Bcr-Abl protein. For this purpose, we developed an ELISA
assay in which a monoclonal anti-c-Abl antibody (Santa
Cruz) is used to capture the Bcr-Abl and c-Abl protein, while
the anti-phosphorylated tyrosine antibody, PY20, is used as a
reporter antibody. Initially, we monitored phosphorylated c-
Abl/Bcr-Abl in a variety of cell lines such as K562, LNCaP,
Cos-1 and Ba/F3 p185 Bcr-Abl. The signal obtained was
very minimal in LNCaP and Cos-1 cells. Furthermore,
signals from K562 and Ba/F3 p185 Bcr-Abl cells were
significantly higher than the background signal. However,
signal-to-noise ratio from Ba/F3 p185 Bcr-Abl was
reproducibly and significantly better than that obtained with
the K562 cells. Thus, we proceeded to investigate the ability of
the D. gibbosa extract in affecting phosphorylation of Bcr-Abl
using Ba/F3 p185 Bcr-Abl. Ba/F3 p185 Bcr-Abl cells were
treated with various concentrations of test compounds for 1 h
and levels of phosphorylated Bcr-Abl were measured as
described in Material and methods. Results shown in Fig. 2
demonstrate that treatment with Imatinib at 0.35-1.5 μM
caused a significant reduction in the phosphorylation status of
Bcr-Abl. In addition, treatment with AG957 caused an inhibition
of the phosphorylation levels of Bcr-Abl in a concentration-
dependent manner. Treatment with 1.75 μM of AG957 cause
a reduction of ~30% of in phosphorylation of Bcr-Abl.
Increasing the drug concentration to 7 μM caused >80%
inhibition of the phosphorylation levels of Bcr-Abl. Similarly,
treatment with 70% ethanol extract of D. gibbosa (Meth 451)
causes a decrease in the phosphorylation levels of Bcr-Abl.
The effect of D. gibbosa extract exhibited a concentration-
dependent phenomenon. Treatment with 100 μg/ml of D.
gibbosa extract caused an almost 50% inhibition in
phosphorylation levels of Bcr-Abl. These data argue that the
anti-CML activity of D. gibbosa extracts might be mediated
by the inhibition of autophosphorylation of Bcr-Abl.
Identification of the active fraction that inhibits Abl
phosphorylation. In an attempt to identify the active moieties
that mediate the activity of the mushroom extracts D. gibbosa
against K562, we used an activity-guided approach to isolate
the active fraction using liquid chromatography. Crude organic
extract was separated on a Silica gel using dichloromethane
and the concentration of methanol was increased. Fractions
were tested for their ability to inhibit autophosphorylation of
Bcr-Abl using our ELISA assays that measure tyrosine
phosphorylation of Abl proteins. As shown in Fig. 3, fractions
F5-F6 contained potent activity that inhibited the autophospho-
rylation of Bcr-Abl, while fraction F7-F8 showed a moderate
inhibitory activity against Bcr-Abl autophopshorylation. In
contrast, fractions F2-F4 showed minimal autophosphorylation
inhibitory activity. We focused on the fraction F6, which was
the most active fraction for the upcoming analysis.
Fraction 6 of the D. gibbosa extract inhibits the auto-
phosphorylation of Bcr-Abl harboring mutations responsible
for Imatinib resistance. To investigate whether fraction 514 F6
is active against mutated Bcr-Abl found in patients' refractory
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Figure 1. Induction of apoptosis by D. gibbosa crude extracts. (A) and (B) induction of PARP cleavage in treated cells by ME424 (A) and Meth451 (B).
Figure 2. Inhibition of Bcr-Abl phosphorylation using ELISA assay. Cells
were treated with the indicated concentration for 1 h and 100 μg of proteins
were used to determine levels of phopshorylated Bcr-Abl.
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to Imatinib treatment, the effect of fraction F6 on the auto-
phosphorylation of Bcr-Abl stably expressed in Ba/F3 cells
was monitored. Bcr-Abl constructs were used harboring
either the E255K, one of the most frequent mutations in Ph+
ALL patients, or the T315I mutation, which confers resistance
not only against Imatinib, but also against most other Abl
kinase inhibitors (16,29,30). Levels of phosphorylated Bcr-Abl
in relation to levels of total Bcr-Abl were determined using
Western blotting. As shown in Fig. 4, crude extract as well as
fraction F6 were able to inhibit the autophosphorylation of not
only the native Bcr-Abl but also of the two mutations Bcr-
Abl; E255K and T315I.
Fraction 6 of the D. gibbosa extract inhibits the colonigenicity
of Ba/F3 cells expressing Bcr-Abl harboring mutations
responsible for Imatinib resistance. In order to evaluate the
biological relevance of the inhibition of the autophosphory-
lation of Bcr-Abl and its kinase mutants, the effect of fraction
F6 on the colonigenicity of Ba/F3 cells expressing native
Bcr-Abl and its mutants was studied. Ba/F3 cells expressing
native Bcr-Abl, Bcr-Abl/T315I or Bcr-Abl/E255K were
plated in the absence of IL-3 in a semi-solid medium and in
the presence and absence of appropriate treatments. Exposure
to fraction F6 as well as to the D. gibbosa crude extract
abolished like Imatinib, the colonigenicity of Bcr-Abl-positive
Ba/F3 cells. While in Ba/F3 cells expressing the Bcr-Abl/
T315I or Bcr-Abl/E255K, no inhibition of colonigenicity
was seen upon exposure to Imatinib; fraction F6 as well as
D. gibbosa organic crude extract completely abrogated the
colony formation of these cells (Fig. 5).
Fraction 6 of D. gibbosa inhibits Abl kinase activity.
Previously, we showed that fraction F6 inhibits the auto-
phosphorylation of Bcr-Abl in Ba/F3 cells trasfected with
Bcr-Abl constructs. Since the experiment was carried out in
cells, one might argue that the observed effect against Bcr-Abl
is indirect and not due to the direct inhibition of the kinase
activity of Bcr-Abl. Thus, we tested the activity of fraction
F6 on the kinase activity of recombinant Abl kinase using
Abltide (EAIYAAPFAKKK) as a substrate.
Results shown in Fig. 6 indicate that fraction F6 inhibited
the in vitro kinase activity of recombinant Abl protein, arguing
that fraction F6 contains substances that directly interfere with
the Abl kinase activity. The experiment was repeated three
times with a comparable outcome. Furthermore, Imatinib at
1 μM was able to inhibit Abl kinase activity by almost 50%.
Similarly, AG957 was active in inhibiting Abl kinase by 50%
at a concentration of 5 μM.
Discussion
CML is a malignancy of pluripotent hematopoietic cells
characterized by the presence of the Philadelphia (Ph)
chromosome, which resulted from reciprocal translocation
between the long arms of chromosomes 9 and 22 {(t(9;22)
q34;q11)} resulting in the creation of the fusion gene p210 Bcr-Abl
exhibiting abnormal tyrosine kinase activity. The presence of
active p210 Bcr-Abl renders CML cells resistant to apoptosis and
delays differentiation.
Medicinal mushrooms have been an important source of
therapeutic substances for the treatment of various human
diseases. Anti-tumor activities from mushrooms were
described in many reports (1,2,4-7).
In many cases, activity was due to HMW polysaccharides
having a molecular weight of 200-400,000 Dalton. Anti-
tumor activity of HMW polysaccharides was attributed to the
immune-modulation function or enhancement properties of the
immune system, not as a result of a direct influence on the
tumor cells.
In this study, we identified mycelium crude extracts of
D. gibbosa, which showed anti-tumor effects against the CML
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Figure 3. Inhibition of autophosphorylation of Bcr-Abl by D. gibbosa
fractions. D. gibbosa fractions were isolated as described in Materials and
methods and were used to evaluate the ability to inhibit Bcr-Abl auto-
phosphorylation. K562 cells were treated with appropriate concentrations of
the fractions for 1 h and cell lysates were used to measure levels of Bcr-Abl
tyrosine phosphorylation as described in Materials and methods.
Figure 4. Inhibition of Abl autophosphorylation of native Abl and its mutants
by Imatinib (A), crude extract (CR) and fraction 6 (F6) (B) compared to
solvent-treated samples (U). BaF/3 cells carrying either native p185 Bcr-Abl
or its mutated forms E255K or T315I were treated for 1 h with Imatinib
(1 μM), crude extract (CR) or active fraction F6 as described in Materials
and methods.
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cancer cell line. The anti-CML activity of D. gibbosa was
observed with each organic extraction; however, selectivity
against other tested cancer cell lines was dependent on the
composition of solvents used during the extraction. For
example, extracts prepared using mixtures H (22% ethyl
acetate, 11% methanol) and C (50% methanol and 33%
chloroform) were CML-selective showing a significant anti-
proliferating activity against the K562 cell line (CML) with
minimal activity against other tested cell lines. However,
extractions with mixtures Eth (70% ethanol) and E (50%
methanol, 33% ethyl acetate) produced crude organic extracts
that are less selective, causing a significant growth inhibition
of MH3924A (rat Morris hepatoma) cell line, but minimal
anti-proliferative activity against other tested cell lines. It is
worth investigating the activities found in Eth and E extracts
missing in extracts H and C, which cause significant
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Figure 5. Effect of active fraction F6 and crude D. gibbosa extract compared to Imatinib on the clonogenicity of Ba/F3 cells expressing either native or mutated
Bcr-Abl (A). (B) A number of stained colonies found in each treatment.
Figure 6. Inhibition of Abl in vitro kinase activity by D. gibbosa active
fraction. The Abl in vitro kinase assay was performed according to
Materials and methods in the presence of AG957 (5 μM), Imatinib (1 μM)
and D. gibbosa active fraction F6 (10 and 100 μg/ml).
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inhibition of the MH3924A (rat Morris hepatoma) cell line.
Our data argue that the two observed anti-proliferation
activities against the K562 (CML) and MH3924A (rat Morris
hepatoma) cell lines might be separated.
Based on the extraction method employed and the ability
to exert biological effects on an in vitro system, we argued
that the active moieties in the organic extraction are not
HMW substances, rather LMW substances.
K562 cells are pluripotent cells that are able to
differentiate along a megakaryocytic, erythroid, or, to a lesser
extent, monocytic lineage. Erythroid differentiation can be
induced by a number of compounds including hemin and
butyric acid (31). The different organic extracts of D. gibbosa
were evaluated for their ability to induce erythroid
differentiation in K562 cells. Each extract was able to
induce hemoglobin expression above the control levels,
however, the Eth extract was the most potent one and
induced hemoglobin expression by >9-fold-treated cells. Our
data show that there is no correlation between anti-
proliferation activity against CML cells and the ability to
induce erythroid differentiation. Eth and C extracts show
comparable anti-proliferation activity against CML, however,
they induced hemoglobin expression by 10.8 and 1.7,
respectively.
It is worth noting that the hemoglobin produced in K562 is
a fetal hemoglobin, mainly γ-globin. Increased expression of
the endogenous γ-globin gene is a realistic approach to
therapy of ß-globin disorders such as sickle cell anemia and
ß-thalassemia (32,33). Thus, our mycelium extract has the
potential to serve as a therapy for ß-globin disorders.
The observed anti-proliferation activity of the organic
extracts of D. gibbosa against K562 was attributed to the
induction of apoptosis. PARP cleavage assay showed that
E and Eth extracts were active at a concentration above
250-300 μg/ml to induce apoptosis in treated cells (Fig. 1).
Similarly, other organic extracts induce apoptosis in K562
with a comparable potency (data not shown).
Bcr-Abl exhibited uncontrolled tyrosine kinase activity,
which accounted for its tumorigenesis. Consequently,
inhibitors of the tyrosine kinase activity of Bcr-Abl were
developed as an effective molecular therapy for the chronic
phase of CML such as Imatinib (STI571; Gleevec). In an
attempt to verify the mechanism of action of our D. gibbosa
organic extracts, we investigated the effect of D. gibbosa
extracts on the kinase activity of Bcr-Abl. Treatment with
the D. gibbosa extract for 1 h caused a significant reduction
in the amount of phosphorylated Bcr-Abl, implying that the
anti-proliferation effect exhibited by D. gibbosa might be
mediated by substances of the extract that interfere with the
phosphorylation process of Bcr-Abl.
Although there are no published reports showing biological
activity or substances isolated from D. gibbosa, anti-tumor
activity from a related species has been reported. D. dickinsii
(Berk.) Bond et al (34) and D. biennis (Bull.) Fr. (35)
showed anti-tumor activity. Active molecules, such as
lanostane triterpenoids and lanostane triterpene glucosides,
were isolated from fruit bodies of D. dickinsii by 70% ethanol
and inhibited the growth of the HL-60 and HCT-15 cell lines.
Furthermore, lanostane triterpene glucosides promoted
apoptosis in the HL-60 cell line (36).
Upon activation, Bcr-Abl becomes autophosphorylated on
multiple tyrosines, making Bcr-Abl tyrosin-phosphorylation a
useful indicator of Bcr-Abl kinase activity. The inhibitory
effects of D. gibbosa fractions on the autophosphorylation of
Bcr-Abl showed that fraction F6 was the most potent in
decreasing the autophosphorylation activity of Bcr-Abl. In
addition, contrary to Imatinib, the D. gibbosa crude extract
and fraction F6 dramatically inhibited the phosphorylation
of the native Bcr-Abl and the two mutated forms including
T315I.
Furthermore, Ba/F3 cells harboring Bcr-Abl are able to
form colonies in soft agar. These studies showed that Imatinib
was able to inhibit colony formation by the Ba/F3 p185
Bcr-Abl cell line. However, it failed to interfere with the
growth of Ba/F3 p185 Bcr-Abl/T315I and Ba/F3 p185 Bcr-
Abl/E255K in soft agar. Conversely, treatment of Ba/F3 p185
Bcr-Abl by either D. gibbosa crude extract or the active
fraction F6 caused an inhibition of colony formation by all
Ba/F3 p185 Bcr-Abl cell lines.
In order to focus on the study of the mechanism of action,
it was necessary to determine whether the active fraction F6
directly inhibits the Bcr-Abl kinase activity. Fraction F6
inhibited 56% of recombinant Abl tyrosine kinase activity in
an in vitro kinase assay at a concentration of 100 μg/ml. The
effect of AG957 on Abl kinase activity is consistent with other
reported data since its activity does not depend on the special
conformation of the enzyme Abl. Contrary to AG957, the effect
of Imatinib in an in vitro Abl kinase assay needed a 5-fold
higher concentration than its effect in previous cell culture
assays. The effect of Imatinib is more potent in the cell culture
assay, since it usually binds to the inactive conformation of the
Bcr-Abl protein.
Our study showed the ability of natural product-derived
substances to regulate the activity of Abl kinase with yet an
undefined mode of action. Several Abl kinase inhibitors are
available and were reported to inhibit the native form of
Bcr-Abl and also most of its mutations that confer a
resistance to Imatinib. However, almost all Abl kinase
inhibitors, except VX-680, failed to inhibit the kinase
activity of the Abl T315I mutation. Our study illustrated that
substances found in the D. gibbosa F6 fraction were able to
inhibit the kinase activity and autophosphorylation function
of the native Abl and its mutants, including T315I. The nature
and the chemical structure of the active moiety remain to be
elucidated.
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